Navigation Links
Not All ADHD Drugs Are Equal

Researchers at the University of Virginia Health System have found that teenage drivers with attention deficit hyper activity disorder (ADHD) drive better when they took// OROS methylphenidate (OROS MPH), a controlled-release stimulant, rather than extended release amphetamine salts (se-AMPH ER). The findings, which reinforce the use of OROS MPH to improve driving performance in teens with ADHD, will appear in the Sept. issue of Pediatrics.

“Car collisions are two to four times more likely to occur among teens with ADHD. Past studies have shown that stimulants commonly used to treat ADHD can help improve driving performance among this group,” said Daniel Cox, Ph.d., lead author and professor of psychiatric medicine at the University of Virginia Health System. “However, there are many different formulations of stimulant drugs to treat ADHD and parents need to know which ones will have the best positive effect.”

In previous studies, Cox and his team set out to determine whether immediate-release and extended release drug formulations influence driving performance throughout the day. They found that OROS MPH (Concerta) compared with immediate-release methylphenidate (Ritalin) was better at improving driving performance. The OROS technology uses osmotic pressure to deliver the drug at a controlled rate.

In this study, researchers compared Concerta to se-AMPH ER (Adderall XR). Both are long-acting stimulants used to treat ADHD. Using a driving simulator, teen drivers between 16 and 19 years of age, displayed their driving skills after taking Concerta, Adderall XR or placebo. Study participants took their medications at 8 a.m. They came to the driving simulator laboratory and completed 15-minute simulated drives at 5 p.m., 8 p.m. and 11p.m. Driving performance was determined by sophisticated computer algorithms.

Researchers found that treatments with Concerta led to fewer inattentive driving errors and less hyperactive or im pulsive driving errors, such as speeding and inappropriate braking, compared with Adderall XR and placebo.

“This was the first study of its kind to demonstrate that OROS methylphenidate has therapeutic benefits among teens for up to 15 hours,” said Cox. “We hope these results encourage teens to be vigilant in taking their medication as prescribed to help contribute to their driving safety and help them appreciate the benefits of stimulant therapy.”

“The study suggests that Concerta should be the initial treatment of choice for teen drivers with ADHD, though teens already on Adderall XR should not necessarily switch medications if they demonstrate a robust therapeutic response”, according to Cox.

In addition, accidents occur most frequently in the evenings and on weekends, meaning parents should not necessarily limit medication use to school days.

Source-Newswie
SRM
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: